Prostate Cancer

New Cancer Drug Satraplatin Predicted To Reach the Market in Mid 2007 for Second-Line Treatment of Patients with Hormone-Refractory Prostate Cancer

Published in Cancer Weekly, May 29th, 2007

Research and Markets has announced the addition of New Cancer Drug Tracker: Satraplatin to their offering.

Long gone are the days when a drug successfully completing Phase III trials was virtually assured of launch.

The results of late-stage clinical trials are scrutinised as never before, and even products that surmount safety and efficacy requirements must overcome increasingly challenging pharmacoeconomic and medical outcome hurdles.

The high cost of new cancer therapies has made them targets for critical analysis. The rewards may be great for patients and companies alike, but...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry